

**SENATE
STATE OF MINNESOTA
NINETY-THIRD SESSION**

S.F. No. 4487

(SENATE AUTHORS: DIBBLE)

DATE
03/04/2024

D-PG

Introduction and first reading
Referred to Health and Human Services

OFFICIAL STATUS

1.1 A bill for an act
1.2 relating to cannabis; permitting the transportation and distribution of medical
1.3 cannabis by manufacturers to a Tribal medical cannabis board, Tribal medical
1.4 cannabis program, and Tribal medical cannabis program manufacturer; amending
1.5 Minnesota Statutes 2022, section 152.29, subdivision 3; Minnesota Statutes 2023
1.6 Supplement, sections 152.29, subdivision 4; 152.33, subdivision 1.

1.7 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.8 Section 1. Minnesota Statutes 2022, section 152.29, subdivision 3, is amended to read:

1.9 Subd. 3. **Manufacturer; distribution.** (a) A manufacturer shall require that employees
1.10 licensed as pharmacists pursuant to chapter 151 be the only employees to give final approval
1.11 for the distribution of medical cannabis to a patient. A manufacturer may transport medical
1.12 cannabis or medical cannabis products that have been cultivated, harvested, manufactured,
1.13 packaged, and processed by that manufacturer to another registered manufacturer, Tribal
1.14 medical cannabis board, Tribal medical cannabis program, or Tribal medical cannabis
1.15 program manufacturer for the other ~~manufacturer~~ entity to distribute.

1.16 (b) A manufacturer may distribute medical cannabis products, whether or not the products
1.17 have been manufactured by that manufacturer.

1.18 (c) Prior to distribution of any medical cannabis, the manufacturer shall:

1.19 (1) verify that the manufacturer has received the registry verification from the
1.20 commissioner for that individual patient;

1.21 (2) verify that the person requesting the distribution of medical cannabis is the patient,
1.22 the patient's registered designated caregiver, or the patient's parent, legal guardian, or spouse

2.1 listed in the registry verification using the procedures described in section 152.11, subdivision
2.2 2d;

2.3 (3) assign a tracking number to any medical cannabis distributed from the manufacturer;

2.4 (4) ensure that any employee of the manufacturer licensed as a pharmacist pursuant to
2.5 chapter 151 has consulted with the patient to determine the proper dosage for the individual
2.6 patient after reviewing the ranges of chemical compositions of the medical cannabis and
2.7 the ranges of proper dosages reported by the commissioner. For purposes of this clause, a
2.8 consultation may be conducted remotely by secure videoconference, telephone, or other
2.9 remote means, so long as the employee providing the consultation is able to confirm the
2.10 identity of the patient and the consultation adheres to patient privacy requirements that apply
2.11 to health care services delivered through telehealth. A pharmacist consultation under this
2.12 clause is not required when a manufacturer is distributing medical cannabis to a patient
2.13 according to a patient-specific dosage plan established with that manufacturer and is not
2.14 modifying the dosage or product being distributed under that plan and the medical cannabis
2.15 is distributed by a pharmacy technician;

2.16 (5) properly package medical cannabis in compliance with the United States Poison
2.17 Prevention Packing Act regarding child-resistant packaging and exemptions for packaging
2.18 for elderly patients, and label distributed medical cannabis with a list of all active ingredients
2.19 and individually identifying information, including:

2.20 (i) the patient's name and date of birth;

2.21 (ii) the name and date of birth of the patient's registered designated caregiver or, if listed
2.22 on the registry verification, the name of the patient's parent or legal guardian, if applicable;

2.23 (iii) the patient's registry identification number;

2.24 (iv) the chemical composition of the medical cannabis; and

2.25 (v) the dosage; and

2.26 (6) ensure that the medical cannabis distributed contains a maximum of a 90-day supply
2.27 of the dosage determined for that patient.

2.28 (d) A manufacturer shall require any employee of the manufacturer who is transporting
2.29 medical cannabis or medical cannabis products to a distribution facility, Tribal medical
2.30 cannabis board, Tribal medical cannabis program, Tribal medical cannabis program
2.31 manufacturer, or to another registered manufacturer to carry identification showing that the
2.32 person is an employee of the manufacturer.

3.1 (e) A manufacturer shall distribute medical cannabis in dried raw cannabis form only
3.2 to a patient age 21 or older, or to the registered designated caregiver, parent, legal guardian,
3.3 or spouse of a patient age 21 or older.

3.4 Sec. 2. Minnesota Statutes 2023 Supplement, section 152.29, subdivision 4, is amended
3.5 to read:

3.6 Subd. 4. **Report.** (a) Each manufacturer shall report to the commissioner on a monthly
3.7 basis the following information on each individual patient for the month prior to the report:

3.8 (1) the amount and dosages of medical cannabis distributed;

3.9 (2) the chemical composition of the medical cannabis; and

3.10 (3) the tracking number assigned to any medical cannabis distributed.

3.11 (b) For transactions involving Tribal medical cannabis program patients, each
3.12 manufacturer shall report to the commissioner on a weekly basis the following information
3.13 on each individual Tribal medical cannabis program patient for the week prior to the report:

3.14 (1) the name of the Tribal medical cannabis program in which the Tribal medical cannabis
3.15 program patient is enrolled;

3.16 (2) the amount and dosages of medical cannabis distributed;

3.17 (3) the chemical composition of the medical cannabis distributed; and

3.18 (4) the tracking number assigned to the medical cannabis distributed.

3.19 (c) Each Tribal medical cannabis board, Tribal medical cannabis program, and Tribal
3.20 medical cannabis program manufacturer that obtains medical cannabis from a manufacturer
3.21 shall report to the commissioner, upon receipt of such medical cannabis, the following
3.22 information:

3.23 (1) the amount and dosages of medical cannabis received;

3.24 (2) the chemical composition of the medical cannabis received; and

3.25 (3) the tracking number assigned to any medical cannabis received.

3.26 Sec. 3. Minnesota Statutes 2023 Supplement, section 152.33, subdivision 1, is amended
3.27 to read:

3.28 Subdivision 1. **Intentional diversion; criminal penalty.** In addition to any other
3.29 applicable penalty in law, a manufacturer or an agent of a manufacturer who intentionally
3.30 transfers medical cannabis to a person other than another registered manufacturer, a Tribal

4.1 medical cannabis board, a Tribal medical cannabis program, a Tribal medical cannabis
4.2 program manufacturer, a patient, a Tribal medical cannabis program patient, a registered
4.3 designated caregiver or, if listed on the registry verification, a parent, legal guardian, or
4.4 spouse of a patient is guilty of a felony punishable by imprisonment for not more than two
4.5 years or by payment of a fine of not more than \$3,000, or both. A person convicted under
4.6 this subdivision may not continue to be affiliated with the manufacturer and is disqualified
4.7 from further participation under sections 152.22 to 152.37.

4.8 Sec. 4. **EFFECTIVE DATE.**

4.9 This act is effective the day following final enactment.